JP2024506020A - サルベコウイルス結合剤 - Google Patents

サルベコウイルス結合剤 Download PDF

Info

Publication number
JP2024506020A
JP2024506020A JP2023547452A JP2023547452A JP2024506020A JP 2024506020 A JP2024506020 A JP 2024506020A JP 2023547452 A JP2023547452 A JP 2023547452A JP 2023547452 A JP2023547452 A JP 2023547452A JP 2024506020 A JP2024506020 A JP 2024506020A
Authority
JP
Japan
Prior art keywords
sarbecovirus
seq
sars
cov
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506020A5 (https=
Inventor
セーレンス，シャビエル
フリーガー，ドリエン デ
ロッシー，アイエブ
カエ，ジークリンデ デ
セデイン，コーエン
シー，レース ファン
エークハウト，ハナ
フィアルコフスカ，ダリア
ストルテレルス，カテライネ
スケーペンス，ベルト
カレベールト，ニコ
レマウト，ハン
ネリンクス，ウィム
ルース，ケニー
ライター，ディルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/052885 external-priority patent/WO2021156490A2/en
Application filed by Vlaams Instituut voor Biotechnologie VIB, Vrije Universiteit Brussel VUB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of JP2024506020A publication Critical patent/JP2024506020A/ja
Publication of JP2024506020A5 publication Critical patent/JP2024506020A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023547452A 2021-02-05 2022-02-07 サルベコウイルス結合剤 Pending JP2024506020A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/052885 2021-02-05
PCT/EP2021/052885 WO2021156490A2 (en) 2020-02-06 2021-02-05 Corona virus binders
EP21166835 2021-04-02
EP21166835.5 2021-04-02
EP21173680.6 2021-05-12
EP21173680 2021-05-12
PCT/EP2022/052919 WO2022167666A1 (en) 2021-02-05 2022-02-07 Sarbecovirus binders

Publications (2)

Publication Number Publication Date
JP2024506020A true JP2024506020A (ja) 2024-02-08
JP2024506020A5 JP2024506020A5 (https=) 2025-02-13

Family

ID=80625002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547452A Pending JP2024506020A (ja) 2021-02-05 2022-02-07 サルベコウイルス結合剤

Country Status (8)

Country Link
US (1) US20240101647A1 (https=)
EP (1) EP4288095A1 (https=)
JP (1) JP2024506020A (https=)
KR (1) KR20230141853A (https=)
AU (1) AU2022216460A1 (https=)
CA (1) CA3207548A1 (https=)
IL (1) IL304929A (https=)
WO (1) WO2022167666A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117794566A (zh) * 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
IT202200025416A1 (it) * 2022-12-13 2024-06-13 Univ Pisa Biosensore per la rilevazione di particelle virali
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4707303A2 (en) 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL HOST & MICROBE, JPN6026001630, 2020, ISSN: 0005773406 *
NATURE COMMUNICATIONS, JPN6026001629, 2020, ISSN: 0005773405 *
NATURE, vol. 583, JPN6026001627, 2020, ISSN: 0005773404 *

Also Published As

Publication number Publication date
IL304929A (en) 2023-10-01
CA3207548A1 (en) 2022-08-11
EP4288095A1 (en) 2023-12-13
US20240101647A1 (en) 2024-03-28
KR20230141853A (ko) 2023-10-10
AU2022216460A1 (en) 2023-09-21
WO2022167666A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
WO2021156490A2 (en) Corona virus binders
US20230227537A1 (en) Corona virus binders
US20240228596A1 (en) Pan-specific corona virus binders
JP2024506020A (ja) サルベコウイルス結合剤
US20250313611A1 (en) Sarbecovirus spike s2 subunit binders
JP2024506315A (ja) コロナウイルスのスパイクタンパク質を標的とする抗体
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
KR20240142594A (ko) 코로나바이러스 sars-cov-2의 스파이크 단백질에 결합할 수 있는 항체
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
Lebedin et al. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
WO2024182862A1 (en) Nanobody for norovirus
WO2024036128A2 (en) Anti-venom antibodies and uses thereof
HK40098138A (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
HK40098138B (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
HK40010475B (zh) Gremlin-1晶体结构和抑制性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260119